Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Investigational new drugs

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1025472712456PMID 14578682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

  2005cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  2002cited by this paper
• Clinical trial designs for cytostatic agents: are new approaches needed?

  2001cited by this paper
• Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

  2000cited by this paper
• EGF receptor.

  1999cited by this paper
• Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

  1999cited by this paper
• Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line

  1998cited by this paper
• Pathological correlates of pituitary adenomas presenting with apoplexy.

  1998cited by this paper
• Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma.

  1997cited by this paper
• Renal-cell carcinoma.

  1996cited by this paper
• The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma.

  1994cited by this paper
• Amplification and overexpression of the epidermal growth factor receptor gene in human renal‐cell carcinoma

  1990cited by this paper
• Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers.

  1989cited by this paper
• Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.

  1989cited by this paper

• A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.

  2022cites this paper
• The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor

  2020cites this paper
• Characterizing the Mechanism of Tumor Suppression by PBRM1 in Clear Cell Renal Cell Carcinoma

  2015cites this paper
• Development of Combination Therapy with Targeted Agents

  2015cites this paper
• The protein tyrosine phosphatase receptor type J is regulated by the pVHL–HIF axis in clear cell renal cell carcinoma

  2013cites this paper
• Targeted Anti-Cancer Therapies for Renal Cancer

  2012cites this paper
• 10. Adrenal Neoplasms

  2012cites this paper
• Malignant Renal Tumors

  2012cites this paper
• Lapatinib and renal cell carcinoma

  2012cites this paper
• Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer

  2012cites this paper
• Regulation of cell growth, death, and polarization by ERBB4

  2011cites this paper
• A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

  2011cites this paper
• EGF receptor inhibitors

  2011cites this paper
• Activated Akt prevents antitumor activity of gefitinib in renal cancer cells.

  2009cites this paper
• The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.

  2009cites this paper
• Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future

  2009cites this paper
• Systemic therapy for advanced renal cell carcinoma

  2009cites this paper
• Review: Systemic therapy for advanced renal cell carcinoma

  2009cites this paper
• Sunitinib in solid tumors

  2009cites this paper
• Targeted therapies for renal cell carcinoma: more gains from using them again

  2009cites this paper
• Signal Transduction Inhibitors in Renal Cell Cancer

  2008cites this paper
• An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.

  2008cites this paper
• Systemic therapy for metastatic renal cell carcinoma.

  2008cites this paper
• Nuevos agentes terapéuticos en cáncer renal avanzado

  2008cites this paper
• Nonsurgical Management of Metastatic Renal Cell Carcinoma

  2008cites this paper
• Signal Transduction Inhibitors in Renal Cell Carcinoma

  2008cites this paper
• Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

  2008cites this paper
• Neue Medikamente beim metastasierten Nierenzellkarzinom

  2008cites this paper
• [New drugs for metastatic kidney cancer].

  2008cites this paper
• Using molecular biology to develop drugs for renal cell carcinoma

  2008cites this paper
• Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

  2008cites this paper
• Targeting angiogenesis in renal cell carcinoma.

  2008cites this paper
• Targeted therapy for advanced renal cell cancer: cytokines and beyond.

  2008cites this paper
• Renal Cell Carcinoma: Overview

  2008cites this paper
• Interferon-&agr; in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

  2008cites this paper
• Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.

  2008cites this paper
• The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents

  2007cites this paper
• New drug therapies for advanced renal cell carcinoma

  2007cites this paper
• Urological cancers in clinical practice

  2007cites this paper
• Integrated therapy of kidney cancer.

  2007cites this paper
• Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma

  2007influential citation
• The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.

  2007cites this paper
• Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines

  2007cites this paper
• Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC

  2007cites this paper
• Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib

  2007cites this paper
• Targeted therapy for metastatic renal cell carcinoma

  2006cites this paper
• VEGF-targeted therapy in renal cell carcinoma: Active drugs and active choices

  2006cites this paper
• Clinical experience with gefitinib: an update.

  2006cites this paper
• Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17.

  2006cites this paper
• The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells

  2006cites this paper
• Clinical implications of the mechanism of epidermal growth factor receptor inhibitors

  2006cites this paper
• Treatment outcome for metastatic papillary renal cell carcinoma patients

  2006cites this paper
• Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel

  2006cites this paper
• Kinase inhibitors in the treatment of renal cell carcinoma.

  2006cites this paper
• Understanding the importance of smart drugs in renal cell carcinoma.

  2006cites this paper
• Targeted approaches for treating advanced clear cell renal carcinoma.

  2006cites this paper
• Kidney cancer: identification of novel targets for therapy.

  2006cites this paper
• A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

  2006cites this paper
• Effect of gefitinib on brain metastases from non-small cell lung cancer.

  2006cites this paper
• Targeted Therapy for Renal Cell Carcinoma: A New Therapeutic Paradigm

  2006cites this paper
• Targeted Approaches for Treating Advanced Clear Cell Renal Carcinoma

  2006cites this paper
• Targeted therapy for metastatic renal cell carcinoma.

  2006cites this paper
• Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents

  2005cites this paper
• [New targets and drugs for treatment of advanced renal cell carcinoma].

  2005cites this paper
• Novel Therapies for Renal Cell Cancer

  2005cites this paper
• Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

  2005cites this paper
• Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: Part 2

  2005cites this paper
• Novel treatment strategies in clear-cell metastatic renal cell carcinoma

  2005cites this paper
• Will the dark sky over advanced renal cell carcinoma soon become brighter?

  2005cites this paper
• Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapy.

  2005cites this paper
• Novel treatments for metastatic renal cell carcinoma.

  2005cites this paper
• Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents

  2005cites this paper
• Current issues in Wilms tumor management.

  2005cites this paper
• Novel treatment strategies in clear-cell metastatic renal cell carcinoma.

  2005cites this paper
• Molecularly targeted therapy in renal cell carcinoma

  2005cites this paper
• Therapeutic approaches in metastatic renal cell carcinoma

  2005cites this paper
• Epidermal growth factor receptor expression in renal cell carcinoma: Rationale for therapy with sidling blockade

  2005cites this paper
• Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.

  2005cites this paper
• What's new in the treatment of metastatic kidney cancer?

  2005cites this paper
• EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients

  2005cites this paper
• Emerging drugs for renal cell carcinoma

  2005cites this paper
• Antiangiogenetische Therapie eines Nieren-Angiomyolipoms bei einer schwerstbehinderten Patientin mit Multipler Sklerose

  2005cites this paper
• Targeted agents for the treatment of advanced renal cell carcinoma.

  2005cites this paper
• Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

  2005cites this paper
• Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

  2005cites this paper
• [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].

  2005cites this paper
• von Hippel–Lindau-associated malignancies: Mechanisms and therapeutic opportunities

  2005cites this paper
• Gateways to clinical trials.

  2004cites this paper
• Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

  2004cites this paper
• Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

  2004cites this paper
• Nouveautés dans la prise en charge du cancer du rein. Stratégie thérapeutique en 2003

  2004cites this paper
• Current treatment of renal cell carcinoma.

  2004cites this paper
• Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?

  2004cites this paper
• Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

  2004cites this paper
• Renal cell carcinoma - innovative medical treatments

  2004cites this paper
• Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

  2004cites this paper
• Bortezomib as a Potential Treatment for Prostate Cancer

  2004cites this paper
• Treatment of recurrent or metastatic renal cell carcinoma

  2004cites this paper